David Malka

21PUBLICATIONS
118CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jul 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

|Apr 22, 2026
Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.

|Oct 06, 2025
Management of biliary tract cancers in elderly patients: a French multicenter retrospective study (PRONOBIL-ACABi).

Marine Valery, Julien Edeline, Julie Henriques

|Apr 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).

Jean-Louis Legoux, Roger Faroux, Nicolas Barrière

|Jan 17, 2024
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.

Christelle De La Fouchardière, David Malka, Claire Cropet

|Sep 28, 2023
Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations.

Anthony Tarabay, Alice Boileve, Cristina Smolenschi

Pageof 4

Frequent Collaborators

6 joint publications

Julien Edeline

5 joint publications

David Tougeron

4 joint publications

Antoine Hollebecque

4 joint publications

Jean-Marc Phelip